First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study von Shi, Yuankai, Song, Yongping, Qin, Yan, Zhang, Qingyuan, Han, Xiaohong, Hong, Xiaonan, Wang, Dong, Zeng, Xiaofeng, Hu, Pei, Zhao, Shuiyu, Hong, Kaka Y., Ma, Chaoming, Cheng, Jiancheng, Ting, Peng, Li, Kevin, Jiang, Weidong, Liu, Scott, Liu, Eugene, Zhang, Xin, Chai, Katherine, Yao, Dan, Luk, Alvin Y.

Volltext